Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Around the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe
Advertisement

Poll Shows Incidence, Adverse Effects of Cancer-Related Fatigue

March 1, 1997
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 6 No 3
Volume 6
Issue 3

NEW YORK--A nationwide survey of US cancer patients, oncologists, and caregivers documents that fatigue has profound effects on patients, including their ability to work, meet family needs, and cope with the disease.

NEW YORK--A nationwide survey of US cancer patients, oncologists, andcaregivers documents that fatigue has profound effects on patients, includingtheir ability to work, meet family needs, and cope with the disease.

The survey, of 419 patients, 197 oncol-ogists, and 200 caregivers, showedthat 78% of cancer patients experience fatigue during the course of theirdisease, with 53% saying they experience fatigue on most days, if not everyday (Figure 1).

While 80% of physicians surveyed said they believe that fatigue is overlookedand undertreated, less than half reported that they discuss it with patientsor attempt to treat it.

"For many patients, fatigue is a daily reminder that they havecancer," said Nicholas Vogelzang, MD, professor of medicine, Universityof Chicago, and one of the authors of the survey. "If we can controlor lessen its effects, we go a long way toward restoring a sense of normalcyto patients' lives."

Some Too Tired to Eat

The survey was conducted by the research organization Wirthlin Worldwidefor The Fatigue Coalition, a multidiscipli-nary group of physicians andpatient advocates from institutions including Harvard, Stanford, MemorialSloan-Kettering, the University of Chicago, and the National Coalitionfor Cancer Survi-vorship. It was underwritten by Ortho Biotech Inc.

The majority of cancer patients reported that fatigue adversely affectstheir ability to work (61%) and interferes with their usual activities(51%), while 42% said that it negatively impacts their ability to takecare of their families (see Figure 2).For some, fatigue makes it difficult even to get out of bed (29%) or toeat their meals (24%).

Psychologically, fatigue also takes a tremendous toll: 57% of patientsin the study said they are unable to enjoy life fully because of fatigue,and 31% said that fatigue affects their hope of successfully fighting theircancer. Some 16% of patients surveyed said that treating their fatiguewas as important as treating the cancer itself, a "small althoughrelevant figure," Dr. Vogelzang said.

Other intriguing findings: While physicians believe that pain is moredebilitating and prevalent than fatigue, 61% of patients say that fatigueaffects their lives more than pain. And while most patients feel that fatigueis caused by their treatment, most physicians believe that the cancer isthe cause, which may explain why most patients (75%) are resigned to livingwith their fatigue.

In response to the survey, The Fatigue Coalition plans to develop aseries of educational and research initiatives designed to help patientsand physicians better understand the onset, duration, and progression offatigue in cancer and how to intervene successfully.

Articles in this issue

Bills Address Women's Health and Cancer Issues
Possible Evolutionary Advantage Seen in Breast Cancer Genes
Physicians Urged to Listen to Tamoxifen Users' Concerns
Neck Check Exam Aims at Early Detection
Upcoming Multicenter Study Will Compare Digital Versus Film Screen Mammography
Investigation Clears Fisher of Scientific Misconduct Charges In NSABP Studies
NCAB to Consider Mammography in Forties
Endocrinologists Issue Clinical Guidelines for Thyroid Cancer
Fatigue May Be Most Under-recognized, Undertreated Cancer-related Symptom
Hormone Replacement Therapy: Making Informed Decisions
AHCPR Issues Colorectal Cancer Screening Evidence Report
Genetic Advances Allow Early Detection of MEN Syndromes
MRI Used to Detect Local Prostate Cancer Recurrence After Prostatectomy
Proposed Budget Increase for NCI Is Below Expected Rate of Inflation
Mammography in One's 40s: Considering the Arguments
Recent Videos
4 experts are featured in this series.
4 experts are featured in this series.
1 expert is featured in this series.
7 experts are featured in this series.
7 experts are featured in this series.
Related Content
Advertisement

The Evolution of Distress Screening in Cancer Care

The Evolution of Distress Screening in Cancer Care

Ariana Pelosci
December 27th 2025
Article

Michelle Riba, MD, discusses the evolution of distress screening in oncology and the move toward a collaborative care model to integrate psychosocial support into clinical practice.


Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Daniel C. McFarland, DO;Michelle Riba, MD
December 22nd 2025
Podcast

Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.


Addressing Sexual and Gender Minority Care in Oncology

Addressing Sexual and Gender Minority Care in Oncology

Ariana Pelosci
December 26th 2025
Article

Daniel C. McFarland, DO, and Charles Kamen, PhD, MPH, discuss the unique challenges that sexual and gender minority groups experience in cancer care.


Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.


Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.

Oncology On the Go Wrapped: The Top 10 Podcast Episodes of 2025

Russ Conroy
December 25th 2025
Article

Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.


Treatment with PT-112 appeared to be well-tolerated among those with recurrent thymoma in a phase 2 trial.

Novel Agent Shows Early Activity in Phase 2 Recurrent Thymoma Study

Russ Conroy
December 24th 2025
Article

Treatment with PT-112 appeared to be well-tolerated among those with recurrent thymoma in a phase 2 trial.

Related Content
Advertisement

The Evolution of Distress Screening in Cancer Care

The Evolution of Distress Screening in Cancer Care

Ariana Pelosci
December 27th 2025
Article

Michelle Riba, MD, discusses the evolution of distress screening in oncology and the move toward a collaborative care model to integrate psychosocial support into clinical practice.


Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Distress Screening: Making the Fifth Vital Sign Integral to Oncology Care

Daniel C. McFarland, DO;Michelle Riba, MD
December 22nd 2025
Podcast

Daniel C. McFarland, DO; and Michelle B. Riba, MD, spoke about distress screening and integrating psychosocial care into oncology.


Addressing Sexual and Gender Minority Care in Oncology

Addressing Sexual and Gender Minority Care in Oncology

Ariana Pelosci
December 26th 2025
Article

Daniel C. McFarland, DO, and Charles Kamen, PhD, MPH, discuss the unique challenges that sexual and gender minority groups experience in cancer care.


Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.

ASH 2025: Key Discussions in Multiple Myeloma, Lymphoma, and Leukemia

Krina K. Patel, MD, MSc;Manali Kamdar, MD;Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath
December 15th 2025
Podcast

Experts share updated results on investigational hematologic oncology regimens that they presented at the 2025 ASH Meeting.


Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.

Oncology On the Go Wrapped: The Top 10 Podcast Episodes of 2025

Russ Conroy
December 25th 2025
Article

Throughout 2025, our podcast highlighted experts who discussed the latest conference data, newly approved drugs, and other oncologic happenings.


Treatment with PT-112 appeared to be well-tolerated among those with recurrent thymoma in a phase 2 trial.

Novel Agent Shows Early Activity in Phase 2 Recurrent Thymoma Study

Russ Conroy
December 24th 2025
Article

Treatment with PT-112 appeared to be well-tolerated among those with recurrent thymoma in a phase 2 trial.

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.